Benzinga | Dec 10, 2020 08:31AM EST

Chardan Capital Maintains Buy on CRISPR Therapeutics, Raises Price Target to $166

Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $110 to $166.